Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 1 of 2)

This article was originally published in PharmAsia News

Executive Summary

When Merck & Co. Inc. Emerging Markets President Kevin Ali speaks of innovation, it is emblematic of Merck's deep-rooted focus on new drug discovery, but the veteran executive now sees opportunities in the differentiated, branded generics segment. On a recent visit to India, Ali spoke to PharmAsia News' India Bureau about incrementally innovative drugs, access to affordable medicines and also Merck's plans in the BRIC-MT nations.
Advertisement

Related Content

Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant
Merck’s ‘Three Pillars’ Strategy Takes Big Step With New Hangzhou Plant
Emerging Markets Earnings Roundup: Bayer And Merck (Part 3)
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
Merck Emerging Markets President Kevin Ali On The Branded Generics Business: An Interview With PharmAsia News (Part 2 of 2)
Innovative, Differentiated Generics To Lead Merck Into EMs, Says Merck EM President Kevin Ali; Prefer Partners Over Buyouts
Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets
Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets
Merck's Chief Strategy Officer Mervyn Turner Talks To PharmAsia News About Partnerships And Transformational Research Models
With More Vaccines For Low-Income Countries In Mind, Merck Signs JV With Wellcome Trust; India To Be Research And Manufacturing Hub
Advertisement
UsernamePublicRestriction

Register

SC078454

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel